In patients with RAS wild‐type (wt) CRC, anti‐epidermal growth factor receptor (anti‐EGFR) therapy has been used2, 3 and immune checkpoint inhibitors such as anti‐PD‐1 and anti‐PDL‐1 antibodies are effective in microsatellite instable (MSI‐high) patients.4 The gene discussed is EGFR; the disease is colorectal carcinoma.